Highlights of our tech platform & competitive edge
Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.
Enabling novel modes of action with favorable benefit-to-risk profiles
We are establishing a proprietary pipeline of differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to differentiate from standard of care by superior efficacy and favorable safety. Our most advanced program, ND021, exemplifies this strategy by blocking immune-suppressive PD-(L)1 signaling with best-in-class potency and simultaneously triggering 4-1BB-mediated T cell stimulation specifically in the tumor microenvironment. ND021 is currently being evaluated in a Phase 1/2 clinical study.
NM21-1480: A novel tri-specific antibody for oncology
Learn more about its unique mode-of-action
Learn more about its unique mode-of-action
×
Latest News
March 31, 2022
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. today…
Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017.
December 14, 2021
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
Numab Therapeutics AG and 3SBio Inc. announced today that 3SBio’s…
Numab Therapeutics AG and 3SBio Inc. announced today that 3SBio’s subsidiary Sunshine Guojian exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager.
May 20, 2021
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
Numab Therapeutics AG today announced the closing of a CHF 100…
Numab Therapeutics AG today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
